Therapy (HCV)

Pegylated Interferon Study Offers Hope for HCV Patients

Published in Hepatitis Weekly, December 7th, 1998

A clinical trial at Virginia Commonwealth University's Medical College of Virginia (MCV) and other institutions has shown that pegylated interferon can reduce titers of the blood-borne virus to undetectable levels.

MCV was one of a dozen sites in the United States participating in the clinical study, funded by F. Hoffmann-LaRoche Ltd. The study followed 155 hepatitis C patients for 48 weeks, 20 of them through MCV.

Results of the trial showed that while patients were taking the pegylated interferon, two-thirds lost all trace of the virus. Twenty-four weeks after ending treatment, 36 percent still had undetectable levels.

By...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry